RETATRUTIDE 120 MG KIT

🧴 RETATRUTIDE 120 MG KIT – 24 MG / VIAL – 5 VIALS – ZPHC PHARMA

🧪 Product Type

Peptide / Multi-Agonist Hormonal Therapy

💉 Active Ingredient

Retatrutide

💉 Dosage Form

Lyophilized powder for reconstitution

💉 Total Kit Strength

120 MG

💉 Vial Strength

24 MG per vial

💉 Package Content

5 vials per kit

📄 Description

RETATRUTIDE by ZPHC Pharma is a next-generation multi-agonist peptide targeting GLP-1, GIP, and glucagon receptors, designed for advanced weight management, metabolic optimization, and type 2 diabetes support. 💉

This formulation is intended for research purposes only, providing insights into how triple agonists influence appetite regulation, insulin sensitivity, and fat oxidation.

🔹 Product Features

• Concentration: 24 MG of Retatrutide per vial
• Total Dose: 120 MG per kit (5 vials × 24 MG)
• Form: Lyophilized powder – requires reconstitution with bacteriostatic water
• Storage: Store refrigerated (2°C–8°C) after reconstitution
• Purity: Pharmaceutical-grade research peptide

✅ Key Research Benefits

🔥 Appetite Suppression: Enhances satiety and reduces caloric intake

💪 Fat Loss & Metabolic Boost: Supports thermogenesis and fat breakdown

💉 Insulin Sensitivity: Improves glucose uptake and beta-cell function

🧪 Triple Receptor Action: Acts on GLP-1, GIP & glucagon receptors for comprehensive metabolic modulation

📈 Suggested Research Use (Investigational Use Only)

Retatrutide is supplied as a lyophilized powder and must be reconstituted with bacteriostatic water before subcutaneous administration.

Dosage, frequency, and duration should follow the parameters of the research protocol.

⚠️ Potential Side Effects (Observed in Research Contexts)

⚠ Nausea or gastrointestinal discomfort

⚠ Reduced appetite

⚠ Mild injection site reactions

⚠ Potential alterations in glucose metabolism

Monitoring is advised during extended study periods.

🚫 Contraindications (Research Advisory)

❌ Not recommended for use in subjects with:

• History of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Known allergy to peptide-based therapeutics

🛒 Purchase Information

For research purposes only – Not for human consumption

Supplied as: 120 MG KIT (5 vials × 24 MG)

Manufacturer: ZPHC PHARMA

Ensure authenticity and quality by ordering through certified research suppliers

​